9 Meters Biopharma begins trial for short bowel syndrome treatment

A clinical trial for a new treatment for short bowel syndrome is under way, according to the manufacturer, 9 Meters Bioparma.The drug, NM-002, is a long-acting, injectable glucagon-like peptide-1 (GLP-1) agonist designed to manipulate gut motility effects in patients with short bowel syndrome by slowing digestive transit time. The drug has already demonstrated safety and extended half-life up to 30 days in a previous study, and it has received orphan drug designation from the FDA.“In developing NM-002, we’ve used Amunix’s proprietary XTEN technology to extend the half-life of the GLP-1Read More

Share on facebook
Share on twitter
Share on linkedin